{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:51:48Z","timestamp":1793944308037,"version":"4.8.0"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Health care systems should strive to achieve outcomes that matter to patients. Limited data exist on the outcomes achieved by patients with cancer with different treatment outcome preferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe treatment outcome preferences among older adults with advanced cancer and explore differences in outcomes between patients prioritizing survival vs quality of life (QoL), testing the hypothesis that patients prioritizing survival would live longer, while those prioritizing QoL would have fewer treatment-related adverse effects (TRAEs) and hospitalizations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This study was an exploratory secondary analysis of the GAP70+ cluster randomized clinical trial conducted at National Cancer Institute\u2019s Community Oncology Research Program centers. Older adults (\u226570 years) with incurable solid tumors or lymphoma and 1 or more impaired geriatric assessment domain(s) who were starting a new systemic cancer treatment as part of the GAP70+ trial were eligible. The primary trial took place between July 29, 2014, and March 13, 2019. All secondary analyses were conducted between January 1, 2025, and May 30, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Patients were divided into 2 cohorts based on their reported preference for prioritizing extending survival vs maintaining QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Treatment outcome preferences, hospitalization, TRAEs, and survival at 6 months and 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 706 patients were included in the analysis. The mean (SD) patient age was 77.2 (5.4) years; 306 (43.3%) were female, and 400 (56.7%) were male. Gastrointestinal (244 patients [34.6%]), lung (175 patients [24.8%]), and genitourinary (109 patients [15.4%]) cancers were the most common. Only 59 patients (8.4%) preferred to prioritize extending survival over maintaining QoL, while 506 patients (71.7%) preferred to prioritize maintaining QoL. No significant associations were identified between cohorts prioritizing survival vs QoL and treatment modifications (risk ratio, 1.03; 95% CI, 0.84-1.27), grade 3 to 5 TRAEs (hazard ratio [HR], 0.84; 95% CI, 0.57-1.23), hospitalization (HR, 0.74; 95% CI, 0.39-1.41), and survival (at 6 months: HR, 0.72; 95% CI, 0.40-1.29; at 1 year: HR, 1.18; 95% CI, 0.81-1.72).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this secondary analysis of a randomized clinical trial, fewer than 1 in 10 older adults with advanced cancer participating in the trial prioritized extending survival over maintaining QoL. Patient preference for extending survival or maintaining QoL was not associated with up-front treatment modifications or downstream outcomes, suggesting a possible lack of responsiveness of the current oncology care delivery system to patient preference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov Identifier<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/study\/NCT02054741\">NCT02054741<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.0072","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:30:50Z","timestamp":1772728250000},"page":"517","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival"],"prefix":"10.1001","volume":"12","author":[{"given":"Daniel R.","family":"Richardson","sequence":"first","affiliation":[{"name":"University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Flannery","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Mohamed","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Magnuson","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wells","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Tylock","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Soto-Perez-de-Celis","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Cancer Center, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"DuMontier","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Dale","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Epstein","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Berenberg","sequence":"additional","affiliation":[{"name":"Hawaii MUNCORP, Honolulu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Ramdin","sequence":"additional","affiliation":[{"name":"Geisinger Cancer Institute NCORP, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Mohile","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah Poh","family":"Loh","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"cbr260002r1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001431.pub6","article-title":"Decision aids for people facing health treatment or screening decisions.","volume":"1","author":"Stacey","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"cbr260002r2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/0272989X211037946","article-title":"Clarifying values: an updated and expanded systematic review and meta-analysis.","volume":"41","author":"Witteman","year":"2021","journal-title":"Med Decis Making"},{"issue":"2","key":"cbr260002r3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/jamaoncol.2019.4728","article-title":"Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program.","volume":"6","author":"Mohile","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10314","key":"cbr260002r4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"cbr260002r5","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1634\/theoncologist.2018-0890","article-title":"Beliefs about advanced cancer curability in older patients, their caregivers, and oncologists.","volume":"24","author":"Loh","year":"2019","journal-title":"Oncologist"},{"issue":"19","key":"cbr260002r6","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1200\/JCO.21.00165","article-title":"Decision making in older adults with cancer.","volume":"39","author":"DuMontier","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15","key":"cbr260002r7","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1002\/cncr.32961","article-title":"Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians.","volume":"126","author":"Williams","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"cbr260002r8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/pon.4241","article-title":"Oncologist, patient, and companion questions during pretreatment consultations about adjuvant cancer treatment: a shared decision-making perspective.","volume":"26","author":"Pieterse","year":"2017","journal-title":"Psychooncology"},{"issue":"7","key":"cbr260002r9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamaoncol.2025.1002","article-title":"Overall survival and quality-of-life superiority in modern phase 3 oncology trials: a meta-epidemiological analysis.","volume":"11","author":"Sherry","year":"2025","journal-title":"JAMA Oncol"},{"issue":"1","key":"cbr260002r10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21638","article-title":"Older adult participation in cancer clinical trials: a systematic review of barriers and interventions.","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"cbr260002r11","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1001\/jama.279.21.1709","article-title":"Relationship between cancer patients\u2019 predictions of prognosis and their treatment preferences.","volume":"279","author":"Weeks","year":"1998","journal-title":"JAMA"},{"issue":"14","key":"cbr260002r12","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1001\/jama.300.14.1665","article-title":"Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment.","volume":"300","author":"Wright","year":"2008","journal-title":"JAMA"},{"issue":"167","key":"cbr260002r13","first-page":"68986","article-title":"Medicare and Medicaid programs and the Children's Health Insurance Program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and policy changes and fiscal year 2025 rates; quality programs requirements; and other policy changes.","volume":"89","year":"2024","journal-title":"Fed Regist"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2845812\/jamaoncology_richardson_2026_br_260002_1779370669.08081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:00:51Z","timestamp":1779375651000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2845812"}},"subtitle":["A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.0072","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}